ライフサイエンスコーパス: interleukin-4

1 CD154, as well as by lipopolysaccharide and interleukin 4.

2 n children who survived, and lower levels of interleukin 4.

3 x vivo with a combination of CD40 ligand and interleukin 4.

4 requires GITR, CD4(+) T cells, B cells, and interleukin-4.

5 M)-CSF-dependent manner but independently of interleukin-4.

6 type on CD8(+) T cells through production of interleukin-4.

7 cells by the quintessential type 2 cytokine, interleukin-4.

8 ced significant increases in serum levels of interleukin-4.

9 to release the immunomodulatory key cytokine interleukin-4.

10 tic cytokines interferon, interleukin-2, and interleukin-4.

11 oduced more gamma interferon (IFN-gamma) and interleukin-4.

12 tumor necrosis factor-alpha (TNF-alpha), and interleukins 4, 10, and 12p70 were determined.

13 Concentrations of the interleukins 4, 10, and 13 were significantly increased

14 phils, 2) serum IgE levels, 3) T2 cytokines (interleukin-4, -13, and -4 to interferon-gamma ratio), a

15 ess syndrome mortality, when increased, were interleukin-4 (18.0 [6.0-54.2]), interleukin-2 (11.8 [4.

16 h2) cells and innate lymphoid cells, such as interleukins 4, 5, and 13, as underlying the eosinophili

17 Gene expression of interleukins 4, 6, and 13, interferon-gamma, tumor necro

18 a sandwich immunoassay for the detection of interleukin-4, a cytokine that promotes proliferation an

19 )-adrenergic receptor (beta(2)AR) on a CD40L/interleukin-4-activated B lymphocyte increases the level

20 hich Arg1 expression is greatly increased by interleukin 4 and 13 signaling through the transcription

21 d children with measles, and lower levels of interleukin 4 and 5.

22 provoked concentrations of interleukin 3 and interleukin 4 and augmented levels of interleukin 12 in

23 NKT cells failed to secrete large amounts of interleukin 4 and interferon-gamma after activation; how

24 table safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pa

25 ations have been seen in atopic asthma, with interleukin 4 and interleukin 13 thought to have a role

26 mation by potently inhibiting the binding of interleukin 4 and interleukin 13 to interleukin-4Ralpha

27 gE, a product of B cells from the actions of interleukin 4 and interleukin 13, is used as treatment f

28 ha monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines i

29 Conversely, minimal interleukin 4 and interleukin 17 production was detected

30 ers have established unanticipated roles for interleukin 4 and the alternative activation of tissue m

31 d produced TH2-inducing cytokines, including interleukin 4 and thymic stromal lymphopoietin, which ar

32 d produced TH2-inducing cytokines, including interleukin 4 and thymic stromal lymphopoietin, which ar

33 pressing accessory cells in media containing interleukin-4 and -10.

34 ith T(FH) cell coexpression of the cytokines interleukin-4 and -21.

35 e immunized with a sopB mutant showed higher interleukin-4 and gamma interferon secretion levels than

36 as associated with increased serum levels of interleukin-4 and immunoglobulins G1 and E directed agai

37 and show substantively lower serum levels of interleukin-4 and interferon-gamma when compared with ma

38 3(+)T-bet(+) cells capable of producing both interleukin-4 and interferon-gamma.

39 r-alpha or interleukin-6 was Int1 dependent; interleukin-4 and interleukin-10 were not detected.

40 Interleukin-4 and Interleukin-13 are cytokines critical

41 TGF-beta signaling also led to a decrease in interleukin-4 and interleukin-13 concentrations, which d

42 receptor alpha monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers

43 f three signaling complexes of the cytokines interleukin-4 and interleukin-13 with their receptors, s

44 fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in

45 T lymphocytes (CTLs) and down-regulation of interleukin-4 and transforming growth factor- beta , lea

46 CD300a expression on memory B cells, whereas interleukin-4 and transforming growth factor-beta1 act a

47 ositive microglia, increased brain levels of interleukins 4 and 10, and reduced levels of CD68, F4/80

48 Local treatment, targeted at inhibition of interleukins 4 and 13 in the lung, could substantially d

49 her levels of Th-1 (interferon-gamma), Th-2 (interleukin-4), and Th-17 (interleukin-17)-associated cy

50 enotype including increased levels of CD127, interleukin 4, and interferon gamma.

51 T cells produced less interferon gamma, interleukin 4, and interleukin 17 upon coculture with B

52 activator interferon gamma, the M2 activator interleukin 4, and M2-associated anti-inflammatory inter

53 nditions blocked up-regulation of GATA-3 and interleukin-4, and in effector/memory CD4(+) T cells, de

54 locyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha and fused

55 evels of transforming growth factor beta and interleukin 4; and fewer myofibroblast infiltration (den

56 Neutralizing interleukin-4 antibody therapy given only in the newborn

57 sphate-buffered saline challenge, except for interleukin-4 at 9 hrs).

58 The former evoked lower interleukin-4, but higher interferon-gamma, mRNA express

59 ependent on basophils, immunoglobulin E, and interleukin-4, but was independent of mast cells.

60 Exposure of peripheral blood monocytes to interleukin-4 can recapitulate the fusion process in vit

61 locyte-macrophage colony-stimulating factor, interleukin-4, CD40L, and interferon-gamma, resulting in

62 ith subsequent assay of interferon-gamma and interleukin 4 cell expression using ELISPOT technique.

63 helper 1 (interferon gamma) and T helper 2 (interleukin-4) cytokine production.

64 ization status in C. neoformans-infected WT, interleukin-4-deficient (IL-4(-/-)), and gamma interfero

65 The levels of interferon gamma- and interleukin 4-dependent induction of the cationic amino

66 iption factor Stat6 plays a critical role in interleukin-4-dependent gene activation.

67 tor-dependent T helper 2 pathway that guides interleukin-4-dependent macrophage polarization, which i

68 chemical inhibition of PARP activity blocked interleukin-4-dependent transcription from target promot

69 pient invariant natural killer T-cell (iNKT) interleukin-4-driven expansion of donor Foxp3(+) natural

70 , in protein ubiquitination, and in insulin, interleukin-4, epidermal growth factor, and platelet-der

71 fibroblasts] responds to stimuli (bleomycin, interleukin-4, etc) with increased latent transforming g

72 exposed to Hb:haptoglobin complexes, but not interleukin-4, expressed the M(Hb) phenotype and were ch

73 early slowly progressing stages, augmenting interleukin-4 expression and protective M2 microglia, an

74 ay be mediated by the augmented secretion of interleukin-4 from mutant Cu2+/Zn2+ superoxide dismutase

75 r levels of mRNAs for PD-1, CD4, CD8, F4/80, interleukin-4, gamma interferon, granzyme A, and granzym

76 tive tumor cells, which we now armed with an interleukin-4 gene (HYPR-Ad-IL4).

77 Interleukin-4 high (IL-4(hi)) FL-TFH cells, unlike FL B

78 In this context, interleukin 4 (IL-4) and granulocyte macrophage colony-s

79 Interleukin 4 (IL-4) and IL-13 are critical for response

80 responses were retained while nonprotective interleukin 4 (IL-4) and IL-5 were diminished.

81 2,6-sialylated glycoform of IgG Fc to induce Interleukin 4 (IL-4) and Signal Transducer and Activator

82 One such macro PARP, PARP-14 alters interleukin 4 (IL-4) and Stat6-dependent transcription.

83 Foxp3 expression was caused by production of interleukin 4 (IL-4) by Ndfip1(-/-) cells.

84 ansforming growth factor-beta (TGF-beta) and interleukin 4 (IL-4) control the differentiation of CD4(

85 Interleukin 4 (IL-4) drives T(H)2 differentiation and IL

86 (iNKT cells) can produce copious amounts of interleukin 4 (IL-4) early during infection.

87 g cytokines interferon gamma (IFN-gamma) and interleukin 4 (IL-4) in the regulation of mycoplasma-spe

88 Interleukin 4 (IL-4) inhibits receptor activator of NF-k

89 Alternative activation with interleukin 4 (IL-4) normalized CGD macrophage efferocyt

90 ected deer mice, including activation of the interleukin 4 (IL-4) pathway in T cells and B cells.

91 Th2 cytokines such as interleukin 4 (IL-4) polarize macrophages to a state of

92 ic deficiency in KLF2 but instead was due to interleukin 4 (IL-4) produced by an expanded population

93 We reported distinct interleukin 4 (IL-4) responsiveness and STAT6 signaling

94 e show that interferon-gamma (IFN-gamma) and interleukin 4 (IL-4) signaled to the majority of lymphoc

95 Macrophages stimulated by interleukin 4 (IL-4) to become alternatively (or, M2) ac

96 eukin 4 receptor alpha (IL-4Ralpha)(-/-) and interleukin 4 (IL-4)(-/-) BALB/c mice have indicated tha

97 We have focused here on interleukin 4 (IL-4), a cytokine that protects normal an

98 lon and Igamma1 transcription in response to interleukin 4 (IL-4), hence class switching to IgE and I

99 tact-sensitized mice preferentially produced interleukin 4 (IL-4), IL-10, and IL-17; CD8(+) T cells,

100 matory (M2) macrophage activation, including interleukin 4 (IL-4), IL-13, and FIZZ1.

101 Dec2 promoted expression of interleukin 4 (IL-4), IL-5 and IL-13 during early T(H)2

102 tein CIS, which was substantially induced by interleukin 4 (IL-4), negatively regulated the activatio

103 become lodged in the host liver, evoking an interleukin 4 (IL-4)- and IL-13-mediated dominant CD4(+)

104 is required for the phenotypic conversion of interleukin 4 (IL-4)-activated monocyte-derived F4/80(in

105 H1N1-specific interleukin 4 (IL-4)-producing CD4(+) T-cell frequencies

106 xpression and terminally differentiated into interleukin 4 (IL-4)-producing NKT2 cells or IL-17-produ

107 XCL13 were also necessary for development of interleukin 4 (IL-4)-producing type 2 helper T cells (T(

108 ritic cells (DCs) and basophils positive for interleukin 4 (IL-4).

109 ease in the median fluorescence intensity of interleukin 4 (IL-4; P < .05) and interleukin 10 (IL-10;

110 iven via the alpha-chain of the receptor for interleukin 4 (IL-4Ralpha) is important for immunity to

111 ction/luciferase reporter assays, heightened interleukin-4 (IL-4) -induced activation of target genes

112 n monocytes were differentiated into iDCs by interleukin-4 (IL-4) and granulocyte-macrophage colony-s

113 infected BALB/c-CXCR3(Tg) mice produced more interleukin-4 (IL-4) and IL-10 and less gamma interferon

114 Nematode infection upregulates interleukin-4 (IL-4) and IL-13 and induces STAT6-depende

115 by which the T helper 2 (Th2) cell cytokines interleukin-4 (IL-4) and IL-13 mediate their effects on

116 Interleukin-4 (IL-4) and IL-13 regulate sPLA2 and MUC2 p

117 ifferent class of proinflammatory cytokines, interleukin-4 (IL-4) and IL-13, in the induction of infl

118 kat T cells up-regulated their production of interleukin-4 (IL-4) and IL-17.

119 aracterized by the induction of the cytokine interleukin-4 (IL-4) and the activation of the transcrip

120 l BEAS-2B cells by proinflammatory cytokines interleukin-4 (IL-4) and tumor necrosis factor alpha (TN

121 the control of the archetypal T(H)2 cytokine interleukin-4 (IL-4) and was a fundamental component of

122 Thymic NKT2 cells that produced interleukin-4 (IL-4) at steady state were located in the

123 Splice variants of the interleukin-4 (IL-4) cytokine gene have been described f

124 e combination therapy of gemcitabine with an interleukin-4 (IL-4) cytotoxin composed of IL-4 and trun

125 We show that exposure to interleukin-4 (IL-4) during DC differentiation enhances

126 yte-macrophage colony-stimulating factor and interleukin-4 (IL-4) from normal subjects.

127 hown that the type 2 cell signature cytokine interleukin-4 (IL-4) hampers neutrophil expansion and mi

128 Interleukin-4 (IL-4) has been detected in both human and

129 ere we show an increase in the production of interleukin-4 (IL-4) in p38alpha(-/-) CD4(+) T cells in

130 We investigated the role of interleukin-4 (IL-4) in regulating CNS inflammation usin

131 cells (Tfh cells) are the major producers of interleukin-4 (IL-4) in secondary lymphoid organs where

132 Interleukin-4 (IL-4) is an antiinflammatory cytokine tha

133 Finally, we demonstrate that interleukin-4 (IL-4) is responsible for inducing catheps

134 We further find that interleukin-4 (IL-4) markedly rescues CD79b and sIgM pro

135 that inhibition of Th2 differentiation using interleukin-4 (IL-4) or IL-13 blockade prevents initiati

136 crophage markers by a mechanism dependent on interleukin-4 (IL-4) or interleukin-13 (IL-13) activatio

137 of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression.

138 The interleukin-4 (IL-4) pathway, which has previously been

139 ation in Socs2(-/-) macrophages and enhanced interleukin-4 (IL-4) plus IL-13-induced STAT6 phosphoryl

140 der exposure to S. haematobium eggs triggers interleukin-4 (IL-4) production and makes BALB/c mice su

141 Enhanced T-cell-mediated interleukin-4 (IL-4) production promotes the development

142 TMEV-specific lymphoproliferative responses, interleukin-4 (IL-4) production, and IL-4/gamma interfer

143 as partially mediated by CD4+ T cells and by interleukin-4 (IL-4) production, did not require eosinop

144 was associated with exposure, with increased interleukin-4 (IL-4) production, IL-5 transcription, and

145 n (TSLP) and type 2 immunity, in particular, interleukin-4 (IL-4) production, in mediating hepatic eo

146 which each functioned independently to limit interleukin-4 (IL-4) production.

147 ith the ability of IRF4/PU.1 to activate the interleukin-4 (IL-4) promoter, strongly suggesting a rol

148 -gamma) recall responses rather than reduced interleukin-4 (IL-4) responses, suggesting that immunopa

149 Of the cytokines examined, Ag-specific interleukin-4 (IL-4) T-helper enzyme-linked immunosorben

150 mbinant RSV vectors expressing IFN-gamma and interleukin-4 (IL-4) that allow us to explore the role o

151 ha (TNF-alpha), lipopolysaccharide (LPS), or interleukin-4 (IL-4) to induce classic (M1 and M(LPS)) o

152 We found that continuous interleukin-4 (IL-4) treatment leads to decreased H3K27

153 rates in mice deficient in the Th2 cytokine interleukin-4 (IL-4) via STAT6 mutation in a BALB/c back

154 Whereas interleukin-4 (IL-4) was dispensable for papain-induced

155 Concentration of type-2 cytokine interleukin-4 (IL-4) was significantly less in both grou

156 nd gamma interferon (LPS/IFN-gamma) and with interleukin-4 (IL-4) were used as controls.

157 n NKT-cell-deficient Jalpha18(-/-) hosts and interleukin-4 (IL-4)(-/-) hosts, or when the donor trans

158 thal ischemia, local neurons rapidly produce interleukin-4 (IL-4), a cytokine with potent anti-inflam

159 reduced levels of ileal transcripts encoding interleukin-4 (IL-4), a key mediator of intestinal masto

160 marked reductions in cysteinyl leukotrienes, interleukin-4 (IL-4), and IL-10, and both ATLa and ZK-99

161 production of interferon-gamma (IFN-gamma), interleukin-4 (IL-4), and IL-17.

162 feron were also up-regulated, while eotaxin, interleukin-4 (IL-4), and IL-5 were down-regulated.

163 r expansion is driven by the type 2 cytokine interleukin-4 (IL-4), as well as by M-CSF, which also co

164 S mice exposed to mercury, the production of interleukin-4 (IL-4), but not that of IL-2 or interferon

165 phage-colony stimulating factor (GM-CSF) and interleukin-4 (IL-4), express functional NK1R.

166 Interleukin-4 (IL-4), IL-10, and IL-13 expression and th

167 ited increased production of CD4(+)-specific interleukin-4 (IL-4), IL-5, and IL-13 and CD4(+)Foxp3(+)

168 s of type II immunity, such as production of interleukin-4 (IL-4), IL-5, and IL-13 by whole-lung cell

169 produce a wide range of cytokines, including interleukin-4 (IL-4), IL-5, IL-13, interferon-gamma, IL-

170 Type 2 inflammatory cytokines, including interleukin-4 (IL-4), IL-5, IL-9, and IL-13, drive the c

171 -type and Th2-promoting cytokines, including interleukin-4 (IL-4), IL-5, IL-9, IL-13, IL-31, and thym

172 as an anti-TIM-3 polyclonal Ab, can promote interleukin-4 (IL-4), IL-6, and IL-13 production without

173 pstream stimuli of these pathways, including interleukin-4 (IL-4), IL-6, and IL-13, increased dramati

174 cells was inhibited by even small amounts of interleukin-4 (IL-4), IL-6, and interferon-gamma (IFN-ga

175 onators, the cytokines interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), and tumor ne

176 repair is a subset of a broad repertoire of interleukin-4 (IL-4)- and IL-13-dependent host responses

177 opment but instead promoted the formation of interleukin-4 (IL-4)-committed T follicular helper (Tfh)

178 e lung, surfactant protein A (SP-A) enhanced interleukin-4 (IL-4)-dependent macrophage proliferation

179 press GVHD caused by 5.0 x 10(5) Tcons in an interleukin-4 (IL-4)-dependent mechanism.

180 Macrophages undergoing interleukin-4 (IL-4)-induced alternative activation in t

181 Interleukin-4 (IL-4)-induced T helper (Th) 2 cells promo

182 ly (P </= 0.001) decreased the percentage of interleukin-4 (IL-4)-positive CD4 and CD8 cells in RSV-s

183 ort, we demonstrate that KSHV suppresses the interleukin-4 (IL-4)-stimulated immune response of B-lym

184 rt in mice an unexpected requirement for the interleukin-4 (IL-4)-stimulated program of alternative m

185 enesis depended on Dex-induced inhibition of interleukin-4 (IL-4).

186 cell receptor (BCR), CD40 ligand (CD40L), or interleukin-4 (IL-4).

187 homeostasis and are induced by the cytokine interleukin-4 (IL-4).

188 oduction of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4).

189 range of cytoprotective cytokines including interleukin-4 (IL-4).

190 ased from CLL cells stimulated with CD40 and interleukin-4 (IL-4).

191 expressed significantly increased levels of interleukin-4 (IL-4).

192 ead secrete a potent M2 polarizing cytokine, interleukin-4 (IL-4).

193 Anti-inflammatory cytokines (interleukin 4 [IL-4] and IL-10) were reported to be abse

194 ulatory/anti-inflammatory cytokine response (interleukin-4 [IL-4] plus IL-10 > tumor necrosis factor

195 e Th1 (gamma interferon [IFN-gamma]) or Th2 (interleukin-4 [IL-4]) cytokines, with detailed monitorin

196 tors known to generate either alternatively (interleukin-4 [IL-4]) or classically (macrophage colony-

197 ll functions by anti-inflammatory cytokines (interleukin-4 [IL-4], IL-10, and transforming growth fac

198 tes/macrophages, or the levels of cytokines (interleukin-4 [IL-4], IL-10, gamma interferon, or IL-13)

199 y inflammatory cell influx and Th2 cytokine (interleukin-4 [IL-4], IL-5, and IL-13) content relative

200 n protein of the anti-inflammatory cytokines interleukin 4 (IL4) and IL10.

201 ting of two prototypic regulatory cytokines, interleukin 4 (IL4) and IL10.

202 Treatment with ATRA increased interleukin 4 (IL4) and IL12p70 in plasma of infected pi

203 FN-gamma) and silencing of the gene encoding interleukin 4 (Il4) in T(H)1 cells.

204 Using sensitive interleukin 4 (Il4) reporter alleles, we demonstrate her

205 d M1 macrophages, but failed to do so in the interleukin 4 (IL4)-induced M2 macrophages.

206 domain, long cytoplasmic tail, 2 (KIR3DL2); interleukin 4 (IL4); and interleukin 13 (IL13).

207 Mo-MLV insertion region 1 homolog (BMI1) and interleukin-4 (IL4) expression, resulting in decreased G

208 The four cytokines erythropoietin (EPO), interleukin-4 (IL4), human growth hormone (hGH), and pro

209 hrough the functionally opposing receptor to interleukin-4 (IL4R).

210 Excessive production of interleukin-4 impairs clearance of the fungal pathogen H

211 had lower expression of interferon-gamma and interleukin 4 in the secondary lymphoid tissues.

212 showed that CD4(+) T cells were a source of interleukin-4 in infected CCR2(-/-) mice, but their cont

213 the data indicate that generation of excess interleukin-4 in lungs of H. capsulatum-infected CCR2(-/

214 CD4+/CD25+/FoxP3+ T lymphocytes co-expressed interleukin-4 in the same cell.

215 phage-colony-stimulating factor (GM-CSF) and interleukin-4 induce monocyte differentiation into moDCs

216 Moreover, AR activation upregulated the interleukin-4-induced expression of CCAAT/enhancer-bindi

217 d a positive effect on interferon-gamma- and interleukin-4-induced JAK/STAT activity in HEK293 or HEK

218 Stimulation of B cells with anti-CD40 plus interleukin-4 induces CSR from Cmu to Cgamma1 (IgG1) and

219 Interleukin-4-inducing principle from schistosome eggs (

220 Conversely, interleukin 4 inhibits the killing of intracellular path

221 alpha) and downregulation of Th2 cytokines (interleukin 4, interleukin 5, interleukin 10, interleuki

222 cytokine production showed higher levels of interleukin-4, interleukin-12, and eotaxin mRNA expressi

223 both in vitro and in vivo, with more robust interleukin-4, interleukin-5, and interleukin-13 product

224 Plasma was assayed for interleukin-1beta, interleukin-4, interleukin-5, interleukin-6, interleukin

225 Level of interleukin-1beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin

226 1beta, soluble interleukin-2 receptor-alpha, interleukin-4, interleukin-5, interleukin-7, interleukin

227 Plasma interleukin-1beta, interleukin-4, interleukin-6, interleukin-8, interleukin

228 d significant differences between groups for interleukin-4, interleukin-6, interleukin-9, interleukin

229 Interleukin-4, interleukin-8, granulocyte macrophage col

230 Interleukin-4 is a cytokine widely known for its role in

231 ts of wild-type and cytokine gene-deficient (interleukin-4-knockout [IL-4 (-/-)] and interferon-gamma

232 Interleukin-4, known to be expressed in skin lesions fro

233 f them at the time of infection, reduced the interleukin-4 level in infected CCR2(-/-) mice.

234 An increase in the interleukin-4 level is associated with decreased recruit

235 stantially more immunotherapeutic sustaining interleukin-4 levels and M2 microglia, and resulting in

236 ajor histocompatibility complex class II and interleukin 4 message after helminth infection.

237 ivation; however, some cells produced either interleukin 4 or interferon-gamma but not both.

238 ed decreased interferon-gamma and no sign of interleukin-4 or interleukin-10 hyperproduction.

239 A expression of the T-helper type 2 cytokine interleukin-4 (P = 0.001) than animals without schistoso

240 T cells (P=0.01), and reduced expression of interleukin-4 (P=0.02) in gal-3 null mice suggest possib

241 Moreover, interleukin-4 polarization lowers expression levels of t

242 In vitro interleukin-4-polarization of human primary monocytes in

243 ietic cell transplantation demonstrated that interleukin-4 polarized human T-Rapa cells had a mixed T

244 that nonpolarized (M0) as well as M1 or M2 (interleukin-4) polarized IPSDM shared transcriptomic pro

245 High levels of interleukin-4-positive (IL-4(+)) and tumor necrosis fact

246 In contrast, Itch(-/-) interleukin-4-producing gammadelta T cells, even in the

247 iNKT cell interleukin 4 production and GC migration were critical

248 ivation, but unlike SEA, it fails to trigger interleukin 4 production from basophils.

249 tigen-specific CD4+ T cell proliferation and interleukin 4 production in vitro, and transfer of basop

250 s following the enhancement of virus-induced interleukin-4 production and subsequent DC-SIGN expressi

251 lso suppressed IFN-gamma and, in many cases, interleukin-4 production by CD4+ T cells at concentratio

252 ction, CD301b(+) DC depletion led to blunted interleukin-4 production by OVA-specific OT-II transgeni

253 n delta-toxin, promoted immunoglobulin-E and interleukin-4 production, as well as inflammatory skin d

254 d the possibility that these cells influence interleukin-4 production.

255 Stimulation of B cells with CD40 ligand and interleukin-4 promoted their ability to transinfect hepa

256 The interleukin 4 receptor (IL-4R) is a central mediator of

257 n gamma (IFN-gamma) receptor (IFN-gammaR) or interleukin 4 receptor alpha (IL-4Ralpha) were infected

258 Previous studies comparing interleukin 4 receptor alpha (IL-4Ralpha)(-/-) and inter

259 Focal demyelination in mice lacking IL4I1 or interleukin 4 receptor alpha (IL4Ralpha) results in incr

260 susceptible (Il4ra(F709)) mice with enhanced interleukin-4 receptor (IL-4R) signaling exhibited STAT6

261 s long been established that dimerization of Interleukin-4 receptor (IL-4R) subunits is a pivotal ste

262 ulation of interleukin-1 receptor 1 (IL1r1), interleukin-4 receptor (IL4r), fibroblast growth factor

263 reg) cells in a manner that was dependent on interleukin-4 receptor alpha (IL-4Ralpha) expression in

264 ion, and we demonstrated a role for enhanced interleukin-4 receptor alpha (IL-4Ralpha) expression on

265 monstrated that, during skin repair in mice, interleukin-4 receptor alpha (IL-4Ralpha)-dependent macr

266 Polymorphisms in the interleukin-4 receptor alpha chain (IL-4R alpha) have be

267 Dupilumab, a fully human anti-interleukin-4 receptor alpha monoclonal antibody, inhibi

268 ensitization, this response was dependent on interleukin-4 receptor signaling.

269 oclonal antibody to the alpha subunit of the interleukin-4 receptor, in patients with persistent, mod

270 inants governing the assembly of the type II interleukin-4 receptor, taking advantage of various agon

271 Interleukin-4 receptor-alpha (IL-4Ralpha) mediates the i

272 ergy expenditure in wild-type, Ucp1(-/-) and interleukin-4 receptor-alpha double-negative (Il4ra(-/-)

273 involved in PH etiology, PH still occurs in interleukin-4 receptor-deficient mice under these condit

274 n M2 but not M1 Msmall ef, Cyrillic required interleukin-4 receptor/Stat6.

275 Dupilumab (an anti-interleukin-4-receptor-alpha monoclonal antibody) blocks

276 Using an interleukin 4-reporter system, we show here that CD4(+)

277 A significant interleukin-4 response to the ALK peptides was detected

278 -induced ATM infiltration and potentiator of interleukin-4 responses and point toward a crucial role

279 Interleukin 4 reversed the antifungal activity of GM-CSF

280 regulating t-bet gene expression, decreasing interleukin 4 secretion, and downregulating gata3 gene e

281 sor activities through the regulation of the interleukin-4 signaling cascade.

282 ctivated transforming growth factor beta and interleukin-4 signaling in the lesional skin.

283 yte macrophage colony-stimulating factor and interleukin-4 signaling.

284 in human CLL was induced by stimulation with interleukin 4/soluble CD40 ligand and by stroma cell con

285 gamma interferon and interleukin-12, but no interleukin-4, suggesting an induction of a T helper 1 r

286 Using IgG as a model cross-reactant with the interleukin-4 system, we additionally illustrate techniq

287 st cells may have resulted in a low level of interleukin-4 that contributed to the reduction in the m

288 yte-macrophage colony-stimulating factor and interleukin-4 to generate dendritic cells.

289 In this study, we used interleukin-4 to induce multinucleation of murine bone m

290 erived dendritic cell-mediated regulation of interleukin-4 transcription was dependent on major histo

291 ngal burden despite the fact that it limited interleukin-4 transcription.

292 cells to infected CCR2(-/-) mice suppressed interleukin-4 transcription.

293 sed gamma interferon secretion and increased interleukin-4 transcription.

294 tively activated" M2 macrophages obtained by interleukin 4 treatment, but almost missing in M1 macrop

295 Upon interleukin-4 treatment, AnxA2 stabilizes the cytosolic

296 ess the therapeutic effect of pitrakinra, an interleukin-4 variant that targets allergic Th2 inflamma

297 kine, GIFT4, engineered by fusing GM-CSF and interleukin-4, was previously found to simulate B cell p

298 e, whereas effects on Th2-cell production of interleukin 4 were more variable.

299 tic cells produced interferon gamma, but not interleukin 4, when stimulated with nonstructural 5.

300 g CTLA4-Ig therapy had lower serum levels of interleukin 4, whereas mice receiving anti-TNF therapy h